A phase III, multi-center, randomized, double blind, active and placebo control, single dose trial to demonstrate the efficacy and safety of DWP-450 in adult subjects for treatment of moderate-to-severe glabellar lines

Trial Profile

A phase III, multi-center, randomized, double blind, active and placebo control, single dose trial to demonstrate the efficacy and safety of DWP-450 in adult subjects for treatment of moderate-to-severe glabellar lines

Recruiting
Phase of Trial: Phase III

Latest Information Update: 20 Jul 2017

At a glance

  • Drugs Botulinum toxin A (Primary)
  • Indications Glabellar lines
  • Focus Registrational; Therapeutic Use
  • Acronyms EV003
  • Sponsors Evolus
  • Most Recent Events

    • 20 Jul 2017 According to an Evolus media release, the European Medicines Agency (EMA) has accepted the Marketing Authorization Application (MAA) for DWP-450 for the treatment of adult patients with glabellar lines for review under the Centralized Procedure .The MAA application is supported by the results of this trial.
    • 06 Apr 2017 The trial has been completed in United Kingdom (end date: 27-04-2016), according to the European Clinical Trials Database.
    • 25 May 2016 The trial has been completed in Germany (end date: 27-04-2016), according to the European Clinical Trials Database.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top